FIGURE 3.

Pretreatment with HSP90 inhibitors prevented S1SP-mediated endothelial dysfunction. (A) 4 h of pretreatment with either HSP90 inhibitor (2 μM AUY-922 or AT13387), but not vehicle, prevented S1SP-mediated changes in transendothelial resistance. (B) Western blotting of activated (phosphorylated) and total AKT and IKBα from HLMVEC incubated for 4 h with HSP90 inhibitors before 4 h exposure to S1SP. (C) Immunostaining for VE-cadherin, F-actin, and DAPI of cells incubated 4 h with HSP90 inhibitors (2 μM) and subsequently exposed for 4 h to 20 nM S1SP. Means ± SEM; n = 3–4; *p < 0.05; **p < 0.01; ***p < 0.001 between groups, 1-way ANOVA and Tukey’s post hoc test.